Misolfa (Dienogest, Ethinylestradiol)

Misolfa is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

• Contraception: provides reliable birth control for women of childbearing age.
• Menstrual cycle regulation: helps achieve more regular and predictable menstrual bleeding.
• Acne treatment: may improve hormonal acne by reducing androgen‑mediated sebum production.

• Misolfa combines dienogest, a progestogenic agent, with ethinylestradiol, an estrogen. The estrogen component suppresses follicle‑stimulating hormone, while the progestogen inhibits luteinizing hormone, together preventing ovulation. Additionally, the progestogen thickens cervical mucus and induces endometrial changes that reduce the likelihood of implantation.

Misolfa may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Breast tenderness: temporary swelling or discomfort.
• Headache: occasional mild to moderate pain.
• Spotting or breakthrough bleeding: irregular bleeding between periods.
• Weight change: slight increase or decrease.
• Mood swings: changes in emotional state.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Hypertension: elevated blood pressure requiring medical attention.
• Liver disorders: hepatic adenoma or cholestasis.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Visual disturbances: sudden loss of vision or eye pain.
• Stroke: neurological symptoms indicating cerebrovascular accident.

Before prescribing Misolfa, clinicians should evaluate patient risk factors and counsel on safe use.

• Assess cardiovascular risk: avoid in patients with history of thrombosis or uncontrolled hypertension.
• Screen smoking status: contraindicated in women over 35 who smoke.
• Review hepatic function: liver disease may alter hormone metabolism.
• Consider drug interactions: evaluate concomitant medications that affect hormone levels.
• Avoid use in pregnancy: discontinue immediately if pregnancy is confirmed.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Misolfa can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness.
• Rifampicin or other strong CYP3A4 inducers: can lower plasma hormone concentrations.
• Anticoagulants (e.g., warfarin): may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely)

• Certain antibiotics (e.g., ampicillin, tetracycline): may slightly diminish contraceptive reliability.
• Antifungal agents (e.g., ketoconazole, itraconazole): can raise hormone levels, increasing side‑effect potential.
• St. John’s wort: herbal supplement that may reduce efficacy.
• Selective serotonin reuptake inhibitors: may increase risk of mood changes.